Engineered immune cells take on tough pancreatic cancer
NCT ID NCT06158139
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new gene therapy for people with pancreatic cancer that has returned after standard treatment. The therapy uses a patient's own immune cells, modified to target a protein called B7-H3 on cancer cells, and includes a safety switch to control side effects. The main goal is to see if the treatment is safe and tolerable for up to 27 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rouse the immune system against pancreatic cancer?
- Can a new ultrasound technique spot hidden pancreatic cancers earlier?
- A simple breath test might spot multiple cancers before symptoms appear
- Can we predict psoriasis relapse after biologics? a new study digs into the clues.
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?